Stijn Van Looy

Support Vector machine versus logistic regression modeling for prediction of hospital mortality in critically ill patients with haematological malignancies (2008)

Verplancke, Thierry, Van Looy, Stijn, Benoit, Dominique, Vansteelandt, Stijn, Depuydt, Pieter, De Turck, Filip, ...

Background: Several models for mortality prediction have been constructed for critically ill patients with haematological malignancies in recent years. These models have proven to be equally or more...

A novel approach for prediction of tacrolimus blood concentration in liver transplantation patients in the intensive care unit through support vector regression (2007)

Van Looy, Stijn, Verplancke, Thierry, Benoit, Dominique, Hoste, Eric, Van Maele, Georges, De Turck, Filip, ...

Abstract Introduction Tacrolimus is an important immunosuppressive drug for organ transplantation patients. It has a narrow therapeutic range, toxic side effects, and a blood concentration with wide...

A novel approach for prediction of tacrolimus blood concentration in liver transplantation patients in the intensive care unit through support vector regression (2007)

Van Looy, Stijn, Verplancke, Thierry, BENOIT, DOMINIQUE, Hoste, Eric, Van Maele, Georges, De Turck, Filip, ...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Van Looy, Stijn, Wyns, Bart, Durez, Patrick, Van Den Bosch, Filip, ...

Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-alpha agents, few studies have examined the long-term effects. We evaluated 511 patients...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

Abstract Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-α agents, few studies have examined the long-term effects. We evaluated 511...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity (2006)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, ...

Prediction of dose escalation for rheumatoid arthritis patients under infliximab treatment (2006)

Van Looy, Stijn, Vander Cruyssen, Bert, Meeus, Jeroen, Wyns, Bart, WESTHOVENS, R, DUREZ, P, ...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Van Looy, Stijn, Wyns, Bart, Durez, Patrick, Van Den Bosch, Filip, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

Abstract This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

Comparison of Machine Learning models for prediction of dose increase in patients with rheumatoid arthritis (2005)

Van Looy, Stijn, Meeus, Jeroen, Wyns, Bart, Vander Cruyssen, Bert, Boullart, Luc, De Keyser, Filip

Comparing statistics with machine learning models to predict dose increase of Infliximab for rheumatoid arthritis patients (2005)

Van Looy, Stijn, Vander Cruyssen, Bert, Wyns, Bart, Meeus, Jeroen, De Keyser, Filip, Boullart, Luc

Feature selection in the prediction of Infliximab dose increase (2005)

Van Looy, Stijn, Meeus, Jeroen, Wyns, Bart, Vander Cruyssen, Bert, De Keyser, Filip, Boullart, Luc

Das28 correlates best with the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, WESTHOVENS, R, DUREZ, P, Van Den Bosch, Filip, VEYS, EM, ...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, MALAISE, M, ...

DAS28 is a robust measure of the physician's clinical judgment of response infliximab therapy (2005)

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, WESTHOVENS, R, DUREZ, P, ...

Building decision tree classifiers using a Kohonen self-organizing map (2004)

Van Looy, Stijn, Wyns, Bart, Boullart, Luc, Baeten, Dominique, Hoffman, Ilse, De Keyser, Filip

Weight analysis of a topological map to determine parameter importance (2004)

Wyns, Bart, Van Looy, Stijn, Boullart, Luc, Baeten, Dominique, Hoffman, Ilse, De Keyser, Filip

Identification of synovial histopathological parameters for diagnostic classification of inflammatory arthritis by SAM analysis and neural networks (2004)

Baeten, Dominique, Wyns, Bart, Van Looy, Stijn, Hoffman, Ilse, Veys, Eric, Boullart, Luc, ...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

DAS28 best reflects the physician's clinical judgment of response to infliximab therapy in rheumatoid arthritis patients: validation of the DAS28 score in patients under infliximab treatment

Vander Cruyssen, Bert, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

This study is based on an expanded access program in which 511 patients suffering from active refractory rheumatoid arthritis (RA) were treated with intravenous infusions of infliximab (3...

Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activity

Cruyssen, Bert Vander, Van Looy, Stijn, Wyns, Bart, Westhovens, Rene, Durez, Patrick, Van Den Bosch, Filip, ...

Although there is strong evidence supporting the short-term efficacy and safety of anti-tumour necrosis factor-α agents, few studies have examined the long-term effects. We evaluated 511 patients...

A novel approach for prediction of tacrolimus blood concentration in liver transplantation patients in the intensive care unit through support vector regression

Van Looy, Stijn, Verplancke, Thierry, Benoit, Dominique, Hoste, Eric, Van Maele, Georges, De Turck, Filip, ...